The First Affiliated Hospital with Nanjing Medical University: Carcinoma trials

The registry lists 14 Carcinoma studies with The First Affiliated Hospital with Nanjing Medical University as lead sponsor. 9 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 8Phase 3 2Phase 4 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT06988956Phase 2
• Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After SurgeryRecruitingNCT06762782Phase 2
• Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCCNot yet recruitingNCT06699498Phase 2
• Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell CarcinomaRecruitingNCT06563869Phase 3
• Immunotherapy for Hepatocellular CarcinomaRecruitingNCT06241326
• Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell CarcinomaEnrolling by invitationNCT06048926Not applicable
• Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06010212Phase 1/2
• Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCCRecruitingNCT05775419Not applicable
• Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular CarcinomaRecruitingNCT05613478Phase 3
• The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACECompletedNCT06041425Phase 4
• Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCCStatus unknownNCT05469061Phase 2
• Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver TransplantationStatus unknownNCT05355155Phase 2
• SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular CarcinomaStatus unknownNCT04297202Phase 2
• Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04052152Phase 2